Skip to content

EFFECTIVENESS of ZINC AS an ADJUVANT to STANDARD THERAPY VERSUS STANDARD THERAPY ALONE in CHILDREN

EFFECTIVENESS of ZINC AS an ADJUVANT to STANDARD THERAPY VERSUS STANDARD THERAPY ALONE in CHILDREN (5-10 YEARS) with MODERATE PERSISTENT ASTHMA

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06869798
Enrollment
84
Registered
2025-03-11
Start date
2021-09-01
Completion date
2023-08-28
Last updated
2025-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma in Children

Keywords

asthma in children, zinc, standard therapy, adjuvant

Brief summary

The objective of this study is to compare the effectiveness of zinc as an adjuvant to standard therapy versus standard therapy alone in children with moderate persistent asthma, as assessed by the Asthma Control Test, in terms of: 1. Improvement in asthma control as measured by the Asthma Control Test (ACT) score. 2. Association of continuous variables (e.g., age and duration of illness) and categorical variables (e.g., sex) with asthma control. HYPOTHESIS Zinc as an adjuvant to standard therapy is more effective than standard therapy alone in managing moderate persistent asthma in children.

Detailed description

DESIGN OF STUDY This is a Randomized Controlled Trial. FOLLOW-UP PROTOCOL The patients will be evaluated at the beginning of the study and then followed up at four weeks and eight weeks after enrollment to assess the primary and secondary outcomes. PRIMARY OUTCOME To assess the improvement in asthma control based on the Asthma Control Test (ACT) score at 4 weeks and 8 weeks, respectively. SECONDARY OUTCOMES To observe improvement in: 1. Asthma symptoms and medication use, as recorded in patient diaries. 2. Association of continuous variables (e.g., age, duration of illness) and categorical variables (e.g., sex) with asthma control. SAMPLE SIZE The Calculated sample size is 84 children (42 in each group: Intervention & Control arm). SAMPLING TECHNIQUE Simple random sampling using the lottery method. SAMPLE SELECTION INCLUSION CRITERIA 1\. Children ( 5-10) years. 2. Either gender. 3.Patient diagnosed with asthma according to the operational definition 4.Child with acute exacerbation of asthma EXCLUSION CRITERIA 1. Children with diarrhea and malnutrition 2. Children with pulmonary disease(pneumonia, viral infection,cystic fibrosis) 3. Children with cardiovascular disease. . 4. Children already taking zinc supplementation. STUDY PROCEDURE After approval from the Institutional Review Board of King Edward Medical University, Mayo Hospital, Lahore, all children aged 5 to 10 years, of either gender, diagnosed with asthma as per the operational definition and fulfilling the inclusion criteria, presenting to the Department of Pediatric Medicine, Mayo Hospital, will be enrolled in this study. Verbal and informed written consent will be obtained from the parents/guardians of all participants. Data Collection & Randomization 1\. Demographic data will be collected. 2. A detailed history regarding symptoms, onset, duration of illness, progression, medication, level of asthma control, and general physical and systemic examination will be conducted. 3. Patients with moderate persistent asthma will be identified. 4. Using simple random sampling (lottery method), patients will be assigned into two groups: 1. Group A (Intervention): Standard therapy + Oral Zinc 20mg/day OD for 2 months. 2. Group B (Control): Standard therapy only. Follow-Up & Assessment All patients will be trained to maintain a diary, documenting responses to the 1. Asthma Control Test (ACT) and medication use. 2. Patients will be followed up every 4 weeks for 8 weeks to evaluate asthma control and symptom improvement.

Interventions

Group A (intervention) and Group B (non-intervention). The patients in Group A will receive standard therapy along with oral zinc 20mg/day OD for 2 months. While the patients in Group B will receive only Standard therapy. Then, all the patients of both groups will be trained to maintain diary regarding questionnaire asked in asthma control test, followed up 4 weekly for 8 weeks

Sponsors

King Edward Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

Double Blind

Intervention model description

Randamize clinical trial

Eligibility

Sex/Gender
ALL
Age
5 Years to 10 Years
Healthy volunteers
No

Inclusion criteria

* Children ( 5-10) years. * Either gender. * Patient diagnosed with asthma according to the operational definition * Child with acute exacerbation of asthma

Exclusion criteria

* Children with diarrhea and malnutrition * Children with pulmonary disease(pneumonia, viral infection,cystic fibrosis) * Children with cardiovascular disease. . • Children already taking zinc supplementation.

Design outcomes

Primary

MeasureTime frameDescription
Change in Asthma Control Test (ACT) Scores From Baseline to 8 WeeksBaseline, 4 weeks and 8 WeeksThe effectiveness of zinc as an adjuvant to standard therapy in children with moderate persistent asthma will be assessed by changes in Asthma Control Test (ACT) scores. Scores will be categorized as: * Controlled- if ACT score ≥ 20 * Partially Controlled- if ACT score is 16-19 * Uncontrolled- if ACT score \< 16 The intervention will be considered effective if there is a statistically significant increase in ACT scores from baseline to 8 weeks.
Number of Emergency Visits Due to Asthma ExacerbationBaseline, 4 weeks and 8 WeeksThe total number of emergency visits due to asthma exacerbation will be recorded at each follow-up. A reduction in emergency visits will be considered indicative of effective treatment.

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026